KAT6A and neoplasm: Similarly, heterozygous loss of the gene encoding the histone acetyltransferase MOZ (Kat6a) slowed down the proliferation of malignant B-cells, and pharmacological inhibition of MOZ reduced E2F2 transcription, stopping tumor growth in vivo [84,85].